New BRCA-targeting drug could treat advanced prostate cancer
Talazoparib delayed disease progression in Phase II trial
Read More
Tag: talazoparib
Talzenna bags EU approval for gBRCA-mutated breast cancer
The indication is for patients with inherited BRCA-mutated locally advanced or metatastatic breast cancer.
Read More
Pfizer’s Talzenna cleared for breast cancer
US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.
Read More
Pfizer files PARP inhibitor for breast cancer in US, EU
Regulators on both sides of the Atlantic have accepted for review Pfizer’s PARP inhibitor talazoparib as a treatment for women with a hereditary BRCA mutation.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
